ArticleFrontiers in pharmacology2016
NanoLuc Luciferase - A Multifunctional Tool for High Throughput Antibody Screening.
Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 85 citations in OpenAlex.
- BRET-Based Approaches for Ion Channels: Emerging Applications and Future Directions.Archiv der Pharmazie · 2026Review
- E50A Mutation Increases the Bioluminescence Activity of picALuc.Biosensors · 2026Article
- Advancing NanoLuc Luciferase Stability beyond Directed Evolution and Rational Design through Expert-Guided Deep Learning.ACS catalysis · 2026Article
- Effects of surfactants on luminescence intensity and duration of the minimal luciferase picALuc.Biophysics and physicobiology · 2026Article
- Cell-Free Gene Expression: Methods and Applications.Chemical reviews · 2025Review
- A homogeneous bioluminescent inhibition immunoassay to detect anti-interferon gamma antibodies.Clinical and experimental immunology · 2024Article
- Rapid and Sensitive Detection of Fentanyl and Its Analogs by a Novel Chemiluminescence Immunoassay.Clinical chemistry · 2024Article
- Protocol for HiBiT tagging endogenous proteins using CRISPR-Cas9 gene editing.STAR protocols · 2024Article
- A Comprehensive Exploration of Bioluminescence Systems, Mechanisms, and Advanced Assays for Versatile Applications.Biochemistry research international · 2024Review
- Interference of metal ions on the bioluminescent signal of firefly, Renilla, and NanoLuc luciferases in high-throughput screening assays.Frontiers in chemistry · 2024Article
- Design of an Arabidopsis thaliana reporter line to detect heat-sensing and signaling mutants.Plant methods · 2023Article
- Protein A-Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G.Analytical biochemistry · 2023Article
- Article
- Engineered Amber-Emitting Nano Luciferase and Its Use for Immunobioluminescence ImagingJournal of the American Chemical Society · 2022Article
- Engineering and exploiting synthetic allostery of NanoLuc luciferase.Nature communications · 2022Article
- Cell-Free Protein Synthesis for High-Throughput Biosynthetic Pathway Prototyping.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A molecular toolbox for ADP-ribosyl binding proteins.Cell reports methods · 2021Article
- The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery.RSC medicinal chemistry · 2021Review
- A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.Nanomaterials (Basel, Switzerland) · 2021Article
- Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.Cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the recent development of NanoLuc luciferase (Nluc), a small (19 kDa), highly stable, ATP independent, bioluminescent protein, an extremely robust and ultra high sensitivity screening system has been developed whereby primary hits of therapeutic antibodies and antibody fragments could be characterized and quantified without purification. This system is very versatile allowing cellular and solid phase ELISA but also homogeneous BRET based screening assays, relative affinity determinations with competition ELISA and direct Western blotting. The new Nluc protein fusion represents a "swiss army knife solution" for today and future high throughput antibody drug screenings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.